Eli Lilly & Co. continued to feel the strain of patent expirations for some of its bigger-selling drugs in the first quarter as profit fell 53% and the company lowered its earnings outlook for the year.
from WSJ.com: US Business http://ift.tt/1iQ2P0L
via IFTTT
from WSJ.com: US Business http://ift.tt/1iQ2P0L
via IFTTT
No comments:
Post a Comment